NCT03922321
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) No drug interventions treatment 2 completed NCT01056419
The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy treatment 4 unknown_status NCT02721992
Graves' Orbitopathy and Hypercholesterolemia No drug interventions Not Available Not Available completed NCT02059655
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) treatment 4 completed NCT00430547
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies treatment Not Available completed NCT00697528
Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy No drug interventions Not Available Not Available completed NCT01969019
A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy treatment 4 unknown_status NCT00174057
The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy No drug interventions Not Available Not Available unknown_status NCT02290704
Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People No drug interventions Not Available Not Available unknown_status NCT03426696
Psychological Status and Related Factors of Thyroid Related Eye Disease No drug interventions Not Available Not Available completed NCT03938545
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) No drug interventions treatment 2 terminated NCT01297699
Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) treatment 3 completed NCT06226545
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease No drug interventions treatment 2 active_not_recruiting NCT06588764
Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy No drug interventions treatment Not Available recruiting NCT01999790
Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy No drug interventions treatment Not Available unknown_status NCT03122847
Glucocorticoids and Bone in Graves' Ophthalmopathy Not Available Not Available active_not_recruiting NCT05775185
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy No drug interventions Not Available Not Available completed NCT04598815
Sirolimus for Graves' Orbitopathy (GO) treatment 2 not_yet_recruiting NCT05793359
Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy Not Available Not Available completed NCT02339142
Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease prevention 4 unknown_status NCT01379196
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy treatment 1 / 2 withdrawn NCT03324022
Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease No drug interventions Not Available Not Available unknown_status NCT02203682
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy treatment 2 unknown_status NCT01727973
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy treatment 1 / 2 completed NCT03590080
Impact of Intravenous Methylprednisolone Treatment on Blood Pressure Not Available Not Available completed NCT06112340
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) treatment 2 / 3 recruiting NCT05532072
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy. treatment 0 unknown_status NCT01272414
Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction treatment 4 withdrawn NCT01893450
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment treatment Not Available terminated NCT01114503
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease treatment 2 terminated NCT03535090
Coagulation After Intravenous Methylprednisolone Administration Not Available Not Available completed NCT03278964
Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy No drug interventions treatment Not Available completed NCT05126147
Hydroxychloroquine in Mild Graves' Orbitopathy treatment 4 recruiting NCT04488406
Genetics and Epigenetics of Graves' Orbitopathy No drug interventions Not Available Not Available completed NCT00348413
Thyroid Treatment Trial No drug interventions treatment Not Available completed NCT05345119
Sirolimus in Graves' Orbitopathy Not Available Not Available completed NCT03498417
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy No drug interventions Not Available Not Available completed NCT04876534
Tocilizumab in Active Moderate-severe Graves' Orbitopathy treatment 2 unknown_status NCT03195296
T and B Cells in Graves' Orbitopathy No drug interventions Not Available Not Available completed NCT05276063
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) treatment 2 / 3 active_not_recruiting NCT04391439
Heart Rhythm After Intravenous Methylprednisolone Administration Not Available Not Available completed NCT03667157
Liver Function After Intravenous Methylprednisolone Administration No drug interventions supportive_care 4 completed NCT03131726
Treatment of Graves´Ophthalmopathy With Simvastatin (GO-S) treatment 3 recruiting NCT05678374
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease No drug interventions Not Available Not Available recruiting NCT06275373
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction Not Available Not Available recruiting NCT03708627
Bimatoprost as a Treatment for Graves' Orbitopathy treatment 0 recruiting NCT03066076
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy treatment 3 unknown_status NCT04927468
Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy No drug interventions treatment Not Available unknown_status NCT04704414
Exophthalmometry With 3D Face Scanners No drug interventions diagnostic Not Available unknown_status NCT06510114
A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy treatment 4 not_yet_recruiting NCT06413043
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy treatment Not Available not_yet_recruiting NCT06569758
A Study of GensSci098 in Subjects With Active Thyroid Eye Disease No drug interventions treatment 1 not_yet_recruiting NCT05002998
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study treatment 4 active_not_recruiting NCT05517421
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease treatment 3 recruiting NCT05517447
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease treatment 3 recruiting NCT05987423
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease treatment 3 recruiting NCT06088979
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease No drug interventions treatment 2 recruiting NCT06401044
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease No drug interventions treatment 1 recruiting NCT06557850
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease No drug interventions treatment 1 recruiting NCT06248619
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease treatment 3 recruiting NCT06307613
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease No drug interventions treatment 3 recruiting NCT06307626
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease. No drug interventions treatment 3 recruiting NCT06625398
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) No drug interventions treatment 3 recruiting NCT06625411
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) No drug interventions treatment 3 recruiting NCT05176639
A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( THRIVE ) treatment 3 active_not_recruiting NCT05683496
Efficacy and Safety of Lonigutamab in Subjects with Thyroid Eye Disease (TED) treatment 1 / 2 recruiting NCT06021054
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED) (THRIVE-2) treatment 3 active_not_recruiting NCT06525506
A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease No drug interventions treatment 2 recruiting NCT05776121
Study of ZB001 in Chinese Patients With Thyroid Eye Disease No drug interventions treatment 1 active_not_recruiting NCT05795621
A Study of IBI311 in Subjects With Active Thyroid Eye Disease No drug interventions treatment 2 / 3 completed NCT04359979
Tamsulosin for Thyroid Lid Retraction treatment Not Available unknown_status NCT01738243
Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease treatment 4 terminated NCT05012033
Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting No drug interventions Not Available Not Available recruiting NCT05731154
Development of an AI Solution to Evaluate Clinical Activity of TAO Using Periocular Images Taken by Smartphones in Patients With Thyroid Dysfunction No drug interventions Not Available Not Available completed NCT06384547
A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) No drug interventions treatment 3 recruiting NCT03461211
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study treatment 3 completed NCT05524571
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease treatment 3 recruiting NCT03103607
Disappearance of Graves' Orbitopathy No drug interventions Not Available Not Available completed NCT05331300
A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease No drug interventions treatment 1 / 2 active_not_recruiting NCT06179875
An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies No drug interventions treatment 3 recruiting NCT01927406
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. prevention 4 withdrawn NCT04311606
Anti-VEGF Therapy for Acute Thyroid Eye Disease treatment 2 recruiting NCT02845336
Celecoxib for Thyroid Eye Disease treatment 2 terminated NCT06367517
Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease) Not Available Not Available recruiting NCT04976816
Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease No drug interventions treatment 2 / 3 completed NCT04737330
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) treatment 3 terminated NCT02316691
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease No drug interventions Not Available Not Available terminated NCT05627401
Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's Ophthalmopathy No drug interventions Not Available Not Available recruiting NCT04096612
The Therapeutic Effect of Dysthyroid Optic Neuropathy No drug interventions other Not Available unknown_status NCT06359795
Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease No drug interventions diagnostic Not Available recruiting NCT02393183
The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) treatment 2 / 3 withdrawn NCT06106828
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2) treatment 3 recruiting NCT06389578
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease treatment 1 completed NCT04433936
Corneal Tomographic Parameters in TGD No drug interventions Not Available Not Available completed NCT06467435
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) treatment 1 recruiting NCT04583735
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease treatment 4 completed NCT05241626
AS-OCT of the Cornea in Thyroid Diseases No drug interventions Not Available Not Available unknown_status NCT01798966
Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease No drug interventions diagnostic Not Available completed NCT04040894
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease Not Available Not Available approved_for_marketing NCT03298867
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study treatment 3 completed NCT06235372
Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease No drug interventions Not Available Not Available not_yet_recruiting NCT02422368
The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease treatment 2 / 3 withdrawn NCT00954057
Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED) No drug interventions treatment 2 completed NCT06126783
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease No drug interventions treatment 3 recruiting